The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Alternative clinical outcomes for patients receiving voxelotor for SCD
Robert Clark Brown, MD, PhD, Children’s Healthcare of Atlanta, Atlanta, GA, talks on the FDA approval of voxelotor for patients with sickle cell disease (SCD) based on the ability to increase patients’ hemoglobin 1g above baseline, and discusses studies investigating other clinical outcomes associated with voxelotor therapy. Dr Brown highlights data from the HOPE Kids 2 trial (NCT04218084), which is evaluating the efficacy of voxelotor in pediatric patients aged 2-15 with SCD, and is collecting transcranial Doppler ultrasound (TCD) measurements in participants to assess the risk of stroke. Dr Brown also talks on data from the ActIVe study (NCT04400487) which is measuring actigraphy improvement with voxelotor in patients with SCD or sickle cell anemia. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Robert Clark Brown, MD, PhD, has participated in consultancy work with Global Blood Therapeutics, Imara and Novo Nordisk; and has received research support from Forma Therapeutics, Global Blood Therapeutics, Imara and Novartis.
